Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCND1 | P24385 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875690 | 0.83 | NPC1 (0.47) | SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL27574298 | 0.77 | CDK2 (0.71) | CDK2CCNE1CDK5SMN1; SMN2CDK1 | |
| Hydrochloric Acid SCHEMBL27569438 | 0.73 | CDK2 (0.64) | CDK2CCNE1CDK5SMN1; SMN2CDK1 | |
| SCHEMBL681610 | 0.73 | CDK2 (0.73) | CDK2CCNE1CDK5SMN1; SMN2CDK1 | |
| SCHEMBL5835819 | 0.72 | CDK2 (0.63) | CDK2CCNE1CDK5SMN1; SMN2CDK1 | |
| SCHEMBL13436514 | 0.72 | CDK2 (0.67) | CDK2CCNE1CDK5SMN1; SMN2CDK1 | |
| SCHEMBL6193347 | 0.72 | CDK2 (0.77) | CDK2CCNE1CDK5SMN1; SMN2CDK1 | |
| SCHEMBL5875675 | 0.71 | RAB9A (0.50) | SMN1; SMN2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5836043 | 0.71 | CDK2 (0.61) | CDK2CCNE1CDK5SMN1; SMN2CDK1 | |
| SCHEMBL5835907 | 0.71 | CDK2 (0.61) | CDK2CCNE1CDK5SMN1; SMN2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006504796-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | claimed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | disclosed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | APP, PARK7, IAPP | CDK2 1792/4885CCNE1 1853/4885CDK5 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.